Dr. Patel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
University of Chicago - Section of Hematology/Oncology
5841 S. Maryland Ave, MC2115
Chicago, IL 60637Phone+1 773-834-8206- Is this information wrong?
Summary
- Dr. Patel an expert in the treatment of myeloproliferative diseases, myelodysplastic syndromes, and leukemias. He is an active researcher whose work is focused on the development of clinical trials to investigate novel therapies that may improve the standard of care for patients with myeloid cancers and leukemia. Dr. Patel has published his research in several well-respected peer-reviewed journals including Blood, Blood Advances, British Journal of Haematology, Cancer, JCI Insight, and Bone Marrow Transplantation.
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 2018 - 2021
- McGaw Medical Center of Northwestern UniversityChief Residency, Internal Medicine, 2017 - 2018
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2014 - 2017
- University of Missouri-Columbia School of MedicineClass of 2014
Certifications & Licensure
- IL State Medical License 2014 - 2023
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Clinical Research Training Institute Participant American Society of Hematology
- ASH Abstract Achievement Award American Society of Hematology, 2020
- Inductee Alpha Omega Alpha Honor Medical Society
Clinical Trials
- Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) Start of enrollment: 2021 Mar 02
- A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2022 Aug 05
- A Study of Oral TP-3654 in Patients With Myelofibrosis Start of enrollment: 2019 Dec 16
- Join now to see all
Publications & Presentations
PubMed
- Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.Gregory W Roloff, Satyajit Kosuri, Mariam T Nawas, Adam S DuVall, Anand A Patel, Peter A Riedell, Olatoyosi Odenike, Wendy Stock, Richard A Larson, Michael R Bishop, E...> ;Haematologica. 2024 Apr 11
- Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.Rafael Madero-Marroquin, Emily Dworkin, Howard Weiner, Caner Saygin, Mariam T Nawas, Michael W Drazer, Adam S DuVall, Satyajit Kosuri, Michael J Thirman, Olatoyosi Ode...> ;Leukemia & Lymphoma. 2024 Mar 5
- Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: resul...Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Patel, Jan P Bewersdorf, Adam S ...> ;Blood Cancer Journal. 2024 Feb 20
- Join now to see all
Press Mentions
- Expert Point of View: Anand Ashwin Patel, MDAugust 10th, 2023
- 2023 ASCO ANNUAL MEETING Luspatercept Poised to Become a New First-Line Standard of Care for Transfusion-Dependent, Lower-Risk Myelodysplastic SyndromesJune 2nd, 2023
Professional Memberships
- Member
- Member
- Member
- Member
Hospital Affiliations
- University of Chicago Medical CenterChicago, Illinois
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: